Wells Fargo raised the firm’s price target on Sangamo (SGMO) to $3 from $1 and keeps an Equal Weight rating on the shares. The firm views partnership formation on Fabry program as well as full data from the pivotal study as key catalysts. Wells thinks upside to the stock will be driven by POC of wholly owned ZFP transcription factor neurology programs.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.